Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell Dev. Biol., 15 June 2021

Sec. Molecular and Cellular Pathology

Volume 9 - 2021 | https://doi.org/10.3389/fcell.2021.661461

RETRACTED: miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson’s Disease

Retracted
  • 1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
  • 2Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
  • 3Department of Neuroscience and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
  • 4Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Citation: Oliveira SR, Dionísio PA, Gaspar MM, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ, Amaral JD and Rodrigues CMP (2021) miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson’s Disease. Front. Cell Dev. Biol. 9:661461. doi: 10.3389/fcell.2021.661461

Received: 30 January 2021; Accepted: 19 May 2021;
Published: 15 June 2021; Retracted: 06 October 2025.

Edited by:

Diego Franco, University of Jaén, Spain

Reviewed by:

Isabella Russo, University of Turin, Italy
Yehong Du, Chongqing Medical University, China
Wanli Smith, Johns Hopkins University, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.